Sirolimus plus ADC drugs for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of sirolimus (a targeted therapy) combined with antibody-drug conjugates (ADCs) for advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor that cannot be removed by surgery or has spread to other parts of the body.
- You have at least one tumor that can be measured on scans.
- You are able to do your daily activities with little or no help (ECOG 0 or 1).
- Your major organs (like kidneys, liver, heart) are working well enough.
- You are willing to provide a tumor sample from a prior biopsy or have a new biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This trial is testing an investigational drug called SYS6077 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if this drug is a safe option for patients who have run out of other choices.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.